GetTopicDetailResponse(id=04b9361843f, topicName=單抗, introduction=單抗, content=null, image=null, comments=2, allHits=2167, url=https://h5.medsci.cn/topic?id=36184, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=627, tagList=[TagDto(tagId=627, tagName=單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=924704, encodeId=46ba924e04c0, content=<a href='/topic/show?id=127d3613e1a' target=_blank style='color:#2F92EE;'>#單克隆抗體#</a><a href='/topic/show?id=04b9361843f' target=_blank style='color:#2F92EE;'>#單抗#</a>是目前國(guó)際上最火熱的一類藥物了, objectTitle=綜述：2021年抗體類藥物觀察【附資料下載】, objectType=article, longId=207130, objectId=c8e120e1308b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210203/f4b72829505445ada38de2a756c55a32.jpg, objectUrl=/article/show_article.do?id=c8e120e1308b, replyNumber=0, likeNumber=216, createdTime=2021-02-15, rootId=0, userName=健康達(dá)人, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8e120e1308b, moduleTitle=綜述：2021年抗體類藥物觀察【附資料下載】, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c8e120e1308b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=888893, encodeId=8c948888938a, content=<a href='/topic/show?id=04b9361843f' target=_blank style='color:#2F92EE;'>#單抗#</a>亟待進(jìn)一步研究安全性問(wèn)題, objectTitle=Lancet Oncol：納武單抗新輔助免疫化療大大改善可切除非小細(xì)胞肺癌的預(yù)后, objectType=article, longId=201315, objectId=52d42013159a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/409.jpg, objectUrl=/article/show_article.do?id=52d42013159a, replyNumber=0, likeNumber=192, createdTime=2020-09-28, rootId=0, userName=神盾醫(yī)療局局長(zhǎng)Jack, userId=ab235268530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52d42013159a, moduleTitle=Lancet Oncol：納武單抗新輔助免疫化療大大改善可切除非小細(xì)胞肺癌的預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=52d42013159a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
